Sanofi: end of 'Research and options' phase with Alnylam
(CercleFinance.com) - Sanofi and Alnylam announce that they have agreed to terminate the “research and options” phase of their alliance which they reached in 2014 for the development of ARNi therapeutic agents for the treatment of rare genetic diseases.
Alnylam will continue the development of an additional experimental agent for the treatment of a rare genetic disease up to a certain stage, which has not yet been disclosed. Sanofi will be responsible for the potential pursuit of its development and commercialisation.
Both companies have also decided to amend certain terms of Sanofi's shareholding agreement in Alnylam, in order to give Sanofi the possibility of lifting the commitment to hold Alnylam shares in its possession.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
Alnylam will continue the development of an additional experimental agent for the treatment of a rare genetic disease up to a certain stage, which has not yet been disclosed. Sanofi will be responsible for the potential pursuit of its development and commercialisation.
Both companies have also decided to amend certain terms of Sanofi's shareholding agreement in Alnylam, in order to give Sanofi the possibility of lifting the commitment to hold Alnylam shares in its possession.
Copyright (c) 2019 CercleFinance.com. All rights reserved.